BioStock article: Aptahem gives update on operations and rights issue

Aptahem is making strides in the field of sepsis treatment with its drug candidate Apta-1. Recently, the company announced the completion of a fourth cohort in the ongoing phase I clinical study. Aptahem has also attended key partnering conferences to showcase its potential sepsis treatment. To learn more about this, and the share issue of 28 MSEK between 14 June – 28 June 2023, BioStock talked to CEO Mikael Lindstam.

Read the interview with Aptahem's CEO Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/06/aptahem-gives-update-on-operations-and-rights-issue/

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.

Tags: